The Interventional Pharmacoeconomic Toolbox Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Welcome and Introduction to Vi3C

Sep

Today In Oncology

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Welcome and Introduction to Vi3C

Misconceptions Regarding Skin Cancer Risk in the United States

Advanced Refractory Melanoma Addition of Tilsotolimod to Ipilimumab

Novel Strategy May Enhance Sensitivity of Monitoring Cancer in Blood Samples

Immunotherapy, Radiosurgery Combination and Risk of Radiation Necrosis in Patients With Cancer Who Have Brain Metastases

Can ctDNA Monitoring Help to Predict Melanoma Recurrence